Members of the tumor necrosis factor (TNF) superfamily regulate cell survival and proliferation and have been implicated in cancer. Tweak (TNF-related weak inducer of apoptosis) has pleiotropic biological functions including proapoptotic, proangiogenic and proinflammatory activities. We explored a role for Tweak in mammary gland transformation using a three-dimensional model culture system. Tweak stimulates a branching morphogenic phenotype, similar to that induced by pro-oncogenic factors, in Eph4 mammary epithelial cells cultured in matrigel. Increased proliferation and invasiveness are observed, with a concomitant inhibition of functional differentiation. Levels of matrix metalloproteinase-9 (MMP-9) are significantly increased following Tweak treatment. Notably, MMP inhibitors are sufficient to block the branching phenotype induced by Tweak. The capacity to promote proliferation, inhibit differentiation and induce invasion suggests a role for Tweak in mammary gland tumorigenesis. Consistent with this, we have observed elevated protein levels of the Tweak receptor, Fn14, in human breast tumor cell lines and xenograft models as well as in primary human breast tumors. Together, our results suggest that the Tweak/ Fn14 pathway may be protumorigenic in human breast cancer.
Introduction
Breast cancer arises as a result of dys-regulation of multiple genetic pathways. The multistep process includes perturbations in mechanisms affecting cell proliferation, differentiation, invasion, angiogenesis and apoptosis. Analysis of the molecular pathways underlying tumorigenesis is critical to further our understanding of the genetic basis of disease initiation and progression. Moreover, dissection of the molecular events linked to cancer is critical to the development of novel and effective therapeutics. The tumor necrosis factor (TNF) superfamily is comprised of numerous ligands and receptors, many of which have been implicated in cancer. TNF family members regulate many biological processes, including cell death, proliferation and survival, and are thereby critical for maintaining normal cellular function. However, dysregulation of these pathways can contribute to neoplasia. Several TNF family members including CD30/ CD30 ligand, CD40/CD40 ligand, RANK/RANK ligand and TRAIL/TRAIL receptor are currently being pursued as targets for cancer therapy in a range of tumor types (reviewed in Younes and Kadin, 2003) . Since the biology of TNF family members is often complex, in some cases, it has been a challenge to determine the optimal therapeutic strategy. For example, blockade of CD40 ligand may be beneficial in limiting the survival signal to B cells in lymphoid malignancies. Alternatively, it may be advantageous to activate CD40 to generate an effective T-cell-mediated antitumor response (reviewed in Younes and Kadin, 2003) .
Tweak (TNF-related weak inducer of apoptosis) is a member of the TNF with pleiotropic biological functions (reviewed in Wiley and Winkles, 2003) . As initially described (Chicheportiche et al., 1997) , Tweak can weakly induce death of tumor cells and monocytes (Chicheportiche et al., 1997; Schneider et al., 1999; Nakayama et al., 2000 Nakayama et al., , 2002 Wilson and Browning, 2002) . On the other hand, Tweak has a robust mitogenic effect on endothelial and smooth muscle cells, and promotes endothelial cell migration (Lynch et al., 1999; Wiley et al., 2001; Jakubowski et al., 2002) . Tweak also induces a strong proinflammatory response in various cell types, including upregulation of IL-8 in tumor cell lines (Kaptein et al., 2000; Chicheportiche et al., 2002) ; IL-8 and MCP-1 in HUVEC (Harada et al., 2002) ; IL-8 and IL-6 in astrocytes (Saas et al., 2000) ; and IL-8, IL-6, matrix metalloproteinase-1 (MMP-1), prostoglandin E2, RANTES and IL-10 in human dermal fibroblasts and synoviocytes (Chicheportiche et al., 2002) .
Tweak mediates its effects through its receptor, Fn14 (Wiley et al., 2001) , which signals via NF-kB and mitogen-activated protein kinase (MAPK) pathways (Brown et al., 2003; Saitoh et al., 2003) . Fn14 was originally described as an FGF-1-inducible immediate early response gene (Wiley et al., 2001) . Induction of Fn14 mRNA has also been observed in response to serum, phorbol ester and a variety of other agents (Feng et al., 2000; Wiley et al., 2001) , in human dermal fibroblasts undergoing mechanical stress (Kessler et al., 2001) and in vivo during tissue repair following injury (Feng et al., 2000) . There have been limited reports regarding Fn14 expression in tumors. Fn14 RNA was detected at high levels in a panel of liver cancer cell lines and in three of four human hepatocellular carcinomas, in contrast to low levels in normal liver (Feng et al., 2000) . In glioblastoma multiforme, Fn14 RNA was increased fivefold in 11 of 16 specimens, and Fn14 expression was reproducibly observed in glioma biopsies by in situ hybridization (Tran et al., 2003) . It is proposed that increased Fn14 expression may be positively correlated with glioma grade (Tran et al., 2003) , and accordingly Fn14 levels are increased in when human glioma cell lines are induced to migrate (Mariani et al., 2001; Tran et al., 2003) . In a screen for differentially expressed genes in pancreatic cancer, Fn14 was identified as significantly overexpressed in five of six pancreatic tumor lines (Han et al., 2002) . Finally, when a small panel of tumors was examined (Wiley and Winkles, 2003) , Fn14 mRNA was upregulated relative to normal tissue in a liver and a brain cancer specimen but not in a breast or a kidney tumor specimen. There have been no other reports of Fn14 expression in breast cancer.
In this study, we investigate a potential role for the Tweak pathway in breast cancer. The mammary epithelial cell line, Eph4 (Reichmann et al., 1989; Brinkmann et al., 1995) , was selected as a model system to investigate the effects of Tweak on mammary epithelial cell proliferation, differentiation, apoptosis and invasion. This model has previously been used to study the molecular determinants of processes involved in development and transformation of the mammary gland. Eph4 cells display classic cobblestone morphology in planar cultures and are nontumorigenic when implanted into nude mice. When cultured in a threedimensional (3-D) matrix, Eph4 cells have the capacity to elicit distinct morphological responses including functional differentiation. Branching proliferation and/ or invasive features of transformation have been observed in response to various oncogenic factors when Eph4 cells were cultured in matrigel or collagen gels. HGF induces formation of branched tubules (Brinkmann et al., 1995; Niemann et al., 1998) ; neuregulin stimulates alveolar structures (Brinkmann et al., 1995; Niemann et al., 1998) ; transfection of Cripto promotes branching, duct-like structures (Wechselberger et al., 2001) ; overexpression of Mek1-results in an invasive phenotype (Pinkas and Leder, 2002) ; overexpression of a Ras mutant activating the PI3K pathway causes hyperproliferation (Janda et al., 2002) ; Bcl-6 transfection prevents differentiation (Logarajah et al., 2003) .
Herein, we find that addition of Tweak to Eph4 cells grown in matrigel results in a dramatic branching phenotype, characterized by many properties associated with transformation. In addition, we observe elevated expression levels of the Tweak receptor, Fn14, in human breast cancer. Our data support a role for Tweak in promoting proliferation and invasion, and suggest a potential involvement in tumorigenesis.
Results

Tweak induces branching morphogenesis in matrigel-cultured Eph4 cells
To examine the effect of Tweak on mammary epithelial cells and a potential role in transformation, we employed the Eph4 3-D model system. Matrigelcultured Eph4 cells, grown in minimal media supplemented with hormones, aggregate and, over the course of several days, form spheroid structures composed of lumen surrounded by a single epithelial layer ( Figure 1A ). When HGF is added to the culture, Eph4 cells form branched tubules ( Figure 1A ), as previously reported (Brinkmann et al., 1995; Niemann et al., 1998) . We tested the effects of Tweak in this system. Addition of Tweak results in a dramatic branching phenotype ( Figure 1A ), resembling the effect of HGF. Branching and lumen formation in response to different doses of Tweak was quantitated, as shown in Figure 1B . Notably, the percentage of total aggregates with branched structures increases from approximately 25% in the absence of Tweak to nearly 80% following treatment with 10 ng/ml Tweak, while there is no obvious change in the percentage of structures with lumen formation. The branching effect of Tweak at all of the concentrations tested was significantly increased relative to untreated cultures. The branching phenotype induced by Tweak is significantly inhibited by addition of soluble Fn14 receptor (Fn14-Fc) but not a control IgG2a protein ( Figure 1C, D) , indicating that the effect of Tweak is specific. Thus, at relatively low concentrations, Tweak is capable of inducing branching morphogenesis in matrigel-cultured Eph4 cells.
Increased proliferation and inhibition of differentiation in Tweak-treated Eph4 cells
The effect of Tweak on Eph4 cells grown in matrigel was examined at the histological level. The highly branched pattern of Tweak-treated cells and an abundance of single cells invading into the matrigel are apparent in hematoxylin and eosin-stained sections (Figure 2A ). To determine whether the branching effect of Tweak is a result of proliferation, as opposed to lack of apoptosis, ki-67 and TUNEL stainings were performed. Figure 2B and C shows an increased frequency of proliferative cells in the Tweak-treated samples that is statistically significant. TUNEL staining of adjacent sections revealed few if any apoptotic cells (data not shown). These findings suggest that proliferation rather than apoptosis is responsible for the branching phenotype. To quantify the proliferative branching effect of Tweak at low doses, cells in the branching structures were disaggregated from the spheroids and then counted. Figure 2D illustrates the increased number of single cells in Tweak-treated samples, which was also evident upon replating of the disaggregated cell suspensions onto tissue culture plates (data not shown). Together, these results indicate that Tweak promotes a proliferative response.
To test the ability of Tweak to impact functional differentiation, we examined expression levels of the milk protein b-casein. It was previously reported that when Eph4 cells are cultured in matrigel, b-casein expression is induced, and addition of HGF cultures can inhibit b-casein levels (Niemann et al., 1998 (Figure 3a) . These results were confirmed by Northern blot analysis performed on RNA samples isolated from an independent experiment, with b-casein cDNA as a probe and b-actin as a loading control. The normalized values are presented in Figure 3b . Thus, Tweak induces proliferation accompanied by reduced functional differentiation in the Eph4 model.
MMP-9 is upregulated by Tweak and is required for the branching phenotype
The invasive phenotype of the Tweak-treated Eph4 cells cultured in matrigel suggests a potential involvement of MMPs. The matrix metalloproteinase MMP-9 has previously been shown to be required for branching morphogenesis in a rat mammary epithelial cell model (Lee et al., 2000) . By semiquantitative RT-PCR, we show that MMP-9 expression is highly upregulated in but not a control IgG2a protein (c). In (D), Eph4 aggregate structures were quantified as described above response to Tweak (Figure 4a ). In contrast, addition of HGF to the culture does not induce MMP-9. These results were confirmed at the protein level by ELISA, where we observe significantly increased MMP-9 levels in response to Tweak but not HGF ( Figure 4b ). In contrast to MMP-9, MMP-2 levels are not affected in response to Tweak (Figure 4c ). MMP inhibitors were employed to determine whether MMPs are required for the branching phenotype ( Figure 5A , B). Inhibitor-A inhibits the branching effects of Tweak, with a partial effect at 0.5 mM and full inhibition at 5 mM. Similarly, Inhibitor-B has a partial effect at 0.1 mM and full inhibition of branching at 1 mM. The effects of these inhibitors are likely due to inhibition of MMP-9, since Inhibitor-A exclusively blocks MMP-9 and MMP-2, and we demonstrate that MMP-9 but not MMP-2 is upregulated in this system. In the case of MMP Inhibitor-B, the IC 50 of this inhibitor for MMP-9 is nearly 10-fold lower than for other MMPs. Thus, MMP-9 is upregulated in response to Tweak and is necessary for the Tweak-induced branching phenotype.
Effect of Tweak on Eph4 cells is independent of HGF and TNF
The effects of Tweak on Eph4 cells that we have demonstrated, such as branching morphogenesis and inhibition of differentiation, are nearly identical to those observed in response to HGF (here and Brinkmann et al., 1995; Niemann et al., 1998 Figure 6A ). Furthermore, semiquantitative RT-PCR analysis reveals that addition of Tweak does not result in elevated levels of c-Met ( Figure 6A ). The possibility that HGF may mediate its effects via the Tweak pathway was also ruled out. We observe that addition of Fn14-Fc does not inhibit the branching morphogenic effect of HGF ( Figure 6B ). Thus, Tweak and HGF appear to function independently of each other in eliciting their effects on Eph4 in 3-D culture. We further tested whether the effect of Tweak is dependent on TNF. Treatment of rat mammary epithelial cultures with TNF was previously shown to result in a branching morphogenic phenotype (Ip et al., 1992; Varela et al., 2001 ), similar to our observations in Figure 6A ). To examine whether the branching effect of Tweak is dependent on TNF, we incubated Tweak-treated cultures in the presence of a TNF antibody, which we have previously shown to have blocking activity against the proliferative effect of TNF in an MTT assay. Anti-TNF antibody had no effect on the ability of Tweak to induce branching morphogenesis (data not shown). We conclude that Tweak functions independently of HGF and TNF in its capacity to induce a morphogenic effect on Eph4 cells in 3-D culture.
The Tweak receptor, Fn14, is expressed in human breast tumors
The activities of Tweak in Eph4 cells that we have observed, namely induction of proliferation, reduced differentiation and increased invasion, are characteristic features associated with oncogenes. Indeed, a similar morphogenic response has previously been reported when well-characterized oncogenes, such as HGF and others (Brinkmann et al., 1995; Niemann et al., 1998; Wechselberger et al., 2001; Janda et al., 2002; Pinkas and Leder, 2002) , are introduced into the Eph4 system. Taken together, these observations suggested a possible role for the Tweak/Fn14 pathway in tumorigenesis. We analysed expression of the Tweak pathway in human tumor cell lines. Approximately half of the breast tumor cell lines that we examined were positive by immunohistochemical staining when tested for their ability to bind Tweak. Tweak binding implied the presence of the Tweak receptor, Fn14, and we confirmed expression of Fn14 by immunohistochemical detection with a mouse anti-Fn14 monoclonal antibody, ITEM4 (Table 1) . To investigate whether Fn14 is expressed in tumors, immunohistochemistry was performed on tumors isolated from Fn14-positive cell lines grown in nude mice. As shown in Figure 7 , NCI-ADR and MD-MBA-231 tumors bind Fc-Tweak, but not a control Fc-fusion protein, and binding of Fc-Tweak is specifically blocked by Fn14-Fc but not a control IgG2a protein. We next examined whether Fn14 is expressed in human primary tumors. We detect Fn14 expression by immunohistochemistry with ITEM4 in a majority of breast tumors but only rarely in normal breast tissue samples ( Figure 8A ). The samples were scored as positive when staining was observed in the epithelium ( Table 2 ). Note that our analysis focused on expression in the epithelial content, although we could also detect Fn14 expression in the stroma of several of the tumor and normal samples. Notably, in approximately half of the tumor samples, expression is particularly intense at the socalled leading edge, or tumor-stromal boundary. In situ hybridization was performed on a human breast tumor array to increase sample size, and we similarly observed RNA expression of Fn14 in a majority of tumor samples but not in normal tissue samples ( Figure 8B , Table 2 ). In situ hybridization also allowed us to assess RNA levels of Tweak in the samples. Tweak expression was evident in more than half of the breast tumor samples, in contrast to normal breast tissue where only weak expression was observed in a small minority of the samples (data not shown). Taken together, these results demonstrate that both Fn14 and Tweak are expressed in human breast tumors, at levels elevated relative to normal tissue.
Discussion
Our data support a role for the Tweak/Fn14 pathway in mammary gland tumorigenesis. We have demonstrated striking effects of Tweak in a 3-D mammary epithelial culture model. Notably, Tweak induces a branching morphogenic phenotype, characterized by increased proliferation, an inhibition of functional differentiation and increased invasiveness. These distinct activities of Tweak comprise many of the hallmark features of oncogenes. Furthermore, we have examined expression of the Tweak pathway in human breast tumors and show that the Tweak receptor, Fn14, is detected in a significant percentage of tumors. This is the first report to demonstrate expression of the Tweak/Fn14 pathway in human breast cancer.
Eph4 3-D culture is an in vitro model system that is predictive of in vivo mammary epithelial hyperproliferation and/or oncogenic potential. For example, transgenic mice overexpressing HGF, a factor that induces a phenotype similar to that of Tweak in Eph4 cells cultured in matrigel, develop neoplasms including mammary gland tumors (Takayama et al., 1997) . Similarly, overexpression of Cripto, a factor that induces branching duct-like structures in Eph4 cells, results in mammary gland hyperplasia and tumor formation (M Sanicola, personal communication). Also, the invasive effects in 3-D culture of Mek1 and a Ras mutant activating the PI3K pathway are consistent with the well-characterized oncogenic properties of the Ras, PI3K and Map kinase pathways. We hypothesize that the Tweak/Fn14 pathway may be a novel mechanism of oncogenesis in the mammary gland, with an impact on proliferation, as well as invasion, of tumor cells.
A hallmark feature of tumorigenesis is a diminished capacity for cellular differentiation. We find that, like HGF (Niemann et al., 1998) , Tweak triggers a reduction in b-casein expression levels, suggesting that Tweak is capable of inhibiting functional differentiation. Interestingly, at the macromolecular level, an effect on differentiation is not observed, in that we cannot detect a quantitative change in the percentage of spheroid structures with lumen formation following Tweak treatment. The decrease in b-casein in response to Tweak and HGF may therefore be simply a reflection of the increase in branching structures and indicative of a shift toward proliferation. Indeed, this notion of increased proliferation being accompanied by an inhibition of differentiation is consistent with mammary gland development in vivo where milk production is blocked during tubular branching. Our studies indicate that the effects of Tweak in the Eph4 system are independent of both HGF and TNF. There is a marked similarity between the capacity of both Tweak and HGF to stimulate branching morphogenesis and inhibit functional differentiation. However, we find that Tweak neither upregulates HGF nor its receptor c-Met; conversely, Fn14-Fc does not inhibit HGF-mediated branching morphogenesis. Furthermore, we show that MMP-9 is induced in response to Tweak but not HGF. The effect of Tweak is also TNFindependent, since a blocking anti-TNF antibody does not inhibit branching morphogenesis induced by Tweak. It is interesting that the response to Tweak in Eph4 cells resembles the response to TNF in rat mammary epithelial cells (MEC). Treatment of MEC with TNF induces proliferative, branching morphogenesis involving inhibition of functional differentiation and requiring MMP-9 (Lee et al., 2000 Shea-Eaton et al., 2001) . In both systems, signaling is likely mediated through NF-kB, which presumably mediates the corresponding upregulation of MMP-9 (Bond et al., 1998) . Nevertheless, the signaling mechanism is likely to differ in the two systems. In the case of TNF, an increase in homodimeric p50-binding activity is coincident with the morphogenic effects of TNF (Varela et al., 2001) . In contrast, following stimulation by Tweak, Fn14 signaling leads to activation of both the canonical and the alternative NF-kB pathways (Saitoh et al., 2003) .
We observe increased expression of MMP-9, but not MMP-2, in response to Tweak in Eph4 cells. Moreover, we demonstrate that the branching, invasive phenotype induced by Tweak requires MMP-9. The ability of Tweak to impact expression of MMPs was previously reported in human dermal fibroblasts with induction of MMP-1 following Tweak treatment (Chicheportiche et al., 2002) . Evidently, Tweak can regulate the degradation of specific components of the extracellular matrix (ECM) depending on the cellular milieu. In the context of tumorigenesis, MMPs are thought to promote cancer by degradation of the basement membrane, leading to tumor invasion and metastasis. Upregulation of MMPs, including MMP-9, has indeed been linked to invasion and metastasis (Duffy et al., 2000) . Significantly, the gelatinase MMPs, namely MMP-9 and MMP-2, are thought to be critical in the conversion of breast cancer in situ to invasive lesions, and there is suggestive evidence that these MMPs may be selectively expressed in invasive breast cancers but not in situ lesions (Barsky et al., 1983) . The induction of, and requirement for, MMP-9 in branching of Eph4 cells suggests a potential role for Tweak in tumor invasion. Consistent with this, we detect particularly strong Fn14 expression in human tumors at the so-called leading edge, which comprises the tumor cells bordering on, and invading into, the stroma. Localized increased expression of Fn14 at the leading edge of tumors may induce elevated levels of MMPs, thereby facilitating tumor invasiveness.
It is interesting that in contrast to the proliferative effect of Tweak at low concentrations, we have observed cell death when matrigel-cultured Eph4 cells are treated with high doses of Tweak (JSM, unpublished data). It is well documented that Tweak can induce killing of tumor cell lines (Chicheportiche et al., 1997; Schneider et al., 1999; Nakayama et al., 2000 Nakayama et al., , 2002 Wilson and Browning, 2002) , although the cell death activity associated with Tweak generally requires sensitizing agents, extended incubation periods and/or high concentrations of Tweak. In our studies, we detect significant cell death, confirmed by TUNEL-positive staining (JSM, unpublished data), when matrigelcultured Eph4 cells are treated with relatively high concentrations of Tweak (e.g. 100 ng/ml). Interestingly, when Eph4 cells are grown in 2-D culture, we have observed a cell death, but not a proliferative, effect of Tweak (JSM, unpublished data). We hypothesize that the branching and proliferation effects of low concentrations of Tweak, which we observe when Eph4 cells are cultured in matrigel, more likely mimic the in vivo situation, with growth in three dimensions, the presence of ECM components, and relatively low levels of Tweak.
Our prediction that the Tweak pathway may play a role in tumorigenesis is supported by our expression studies. We examined a large panel of human breast tumor cell lines and primary tumors, and we have detected Fn14 expression in a high proportion of the samples. In contrast, we rarely detect Fn14 expression in normal breast tissue samples. As further evidence that expression of the Tweak/Fn14 pathway is relatively high in tumors, we can detect binding to Fc-Tweak immunohistochemically in tumor cell lines and xenograft tumors but not in any normal tissues that are receptorpositive at the RNA level (JSM and LB, unpublished data) . In previous reports of Fn14 expression in tumors, relatively small numbers of tumors were examined and the analysis has been almost exclusively at the RNA level (Feng et al., 2000; Han et al., 2002; Tran et al., 2003; Wiley and Winkles, 2003) . With respect to breast cancer, only a single RNA sample was analysed and found not to be overexpressed (Wiley and Winkles, 2003) . Thus, this is the first demonstration of Fn14 expression at the protein level in a significant number of human breast tumors. Of note, we have also observed detectable levels of Tweak RNA in tumor but only rarely in normal breast tissue, suggesting that both ligand and receptor are likely present in the tumors. Our studies predict that it may be beneficial to block the Tweak pathway as a therapeutic modality in cancer. The previously reported ability of Tweak to induce angiogenesis (Lynch et al., 1999; Wiley et al., 2001; Jakubowski et al., 2002) suggests an additional potential benefit of blocking Tweak in cancer, namely inhibition of the blood supply to tumors. Thus, blocking Tweak could be advantageous, with a combined effect of inhibiting both the tumor cells directly, as first suggested here, as well as the vascular supply. While a rationale for blocking Tweak in cancer is evident, the concept of delivering Tweak at high levels as a mechanism by which to kill tumor cells cannot be ruled out (Chicheportiche et al., 1997; Schneider et al., 1999; Nakayama et al., 2000 Nakayama et al., , 2002 Wilson and Browning, 2002) . This complexity, namely reasonable justification for opposing approaches to cancer treatment, is not unique to Tweak. For other TNF family members, such as CD40 ligand, the relative benefits of blocking versus activating the pathway have similarly been discussed (Younes and Kadin, 2003) . The apparent dual role of cytokines in cancer has recently been reviewed (Dranoff, 2004) . Our data nevertheless are consistent with the notion of Tweak/Fn14 as a potentially oncogenic pathway. The observed overexpression of Fn14 in human breast tumors, coupled with the oncogenic features of Tweak exemplified in the mammary epithelial model presented here, make the Tweak/Fn14 pathway a potentially attractive candidate for targeted therapy in breast cancer.
Materials and methods
Protein reagents
The Fc-Tweak construct was generated by fusing the Fc portion of human IgG1 (Gaide and Schneider, 2003) to the amino terminus of a cDNA fragment encoding soluble human Tweak (aa 106-249). The construct was transfected into 293T cell line to generate a stable expression line for protein production and subsequent protein-A purification. To generate the Fn14-Fc construct, a cDNA fragment encoding the extracellular portion of mFn14 (aa 1-75) was ligated to the pEAG293 vector-containing mouse IgG2a. The resulting Fn14-Fc was subsequently subcloned into the pV90 vector for stable expression in a CHO cell line.
The previously described anti-Tweak monoclonal antibody, ITEM4 , was purchased from eBiosciences. The neutralizing anti-TNF monoclonal antibody, clone G281-2626, was purchased from Pharmingen.
Eph4 culture
Eph4 cells were cultured in matrigel-coated six-well plates (BD Biosciences), similar to previously described (Niemann et al., 1998) . Briefly, 3.5 Â 10 6 Eph4 cells (kind gift of D Salomon, NCI) (Brinkmann et al., 1995; Niemann et al., 1998) were plated in MEGM media (Clonetics) supplemented with 10% fetal bovine serum on day 1. On day 2, the medium was replaced with serum-free MEGM with the following additional factors (Clonetics): bovine pituitary extract (52 mg/ml), hydrocortisone (0.5 mg/ml) and insulin (5 mg/ml). Eph4 experiments were terminated at day 8, with daily replacement of medium plus factors. Unless otherwise stated, analyses were performed on day 8. Where indicated, HGF (BD Biosciences) at 20 ng/ml, or Fc-Tweak at specified concentrations was added daily, beginning at day 1. Note that similar results were observed with both Fc-Tweak as well as a recombinant soluble form of Tweak. For histological analysis, matrigel pieces were fixed in neutral-buffered formalin overnight prior to paraffin embedding. For disaggregation of branching structures, matrigel cultures were processed with BD cell recovery solution (BD Biosciences) and single cells were counted.
RNA and Northern blot
RNA was prepared from matrigel cultures using the BD cell recovery solution (BD Biosciences) followed by RNA-STAT-60 (Tel-Test). Northern blot analysis was performed on 10 mg of total RNA as previously described (Michaelson and Leder, 2001) . A cDNA probe for b-casein was generated by RT-PCR (see below), and a human cDNA control probe for human b-actin was purchased (BD Biosciences).
RT-PCR
RT was performed with the Superscript First Strand Synthesis System (Invitrogen). For PCR analysis, the cycle number was optimized to allow for semiquantitative analysis. The cycle numbers, annealing temperatures, product sizes and oligonucleotides are as follows. GAPDH: 18 cycles, 571C, 438 bp. 5 
Immunohistochemistry
Immunohistochemistry was performed on frozen sections of human tumor cell lines or tissues. All sections were briefly acetone-fixed, preblocked with avidin/biotin blocking kit (Vector), and treated with 0.3% H 2 O 2 for 10 min. For staining with Fc-Tweak, sections were blocked with 4% goat serum, incubated with 2.5 mg/ml Fc-Tweak in 0.1% BSA/PBS for 1 h, followed by incubation with biotinylated goat antihuman Fc at 1 : 500 (Jackson) in 0.1% BSA/PBS for 30 min. Fc-Tweak was preincubated with (25 mg/ml) Fn14-Fc or a control IgG2a protein (p1.17) for 30 min where indicated. For staining with ITEM4 (3 mg/ml), the Vectastatin Universal kit ABC (Vector) was used. Detection was performed with StreptABComplex/HRP (Dako) followed by DAB (Vector) for 4-5 min. Frozen human tumor and normal breast samples were obtained from Asterand, and as a kind gift of Lawrence Zuckerberg, MGH.
In situ hybridization
Cancer arrays were purchased from Imgenix. High specific activity probes were synthesized using an Ambion T7 Maxiscript in vitro transcription kit and 33 P-radiolabeled UTP (>3000 Ci/mmol, Perkin Elmer), according to the manufacturer's instructions. All probes were used in a hybridization buffer containing 30 000 counts/min/ml final probe concentration. Microscopic analysis of the expression patterns was performed on a Leica DMR system modified for reflective darkfield microscopy. Images were captured using a CoolSnap RGB camera, processed in Open Lab, and polished using Photoshop 7.0. FN14 riboprobe templates were generated using specific PCR primers containing a T7 polymerase promoter-binding site on either the forward or reverse primer to generate sense or antisense templates, respectively. The 330 base pair Fn14 riboprobe template is specific for nucleotides 117-447 in the human Fn14 (TNFRSF12A) coding domain (Genbank: BC002718.2). This region corresponds to the four coding exons of the Fn14 gene.
Tweak riboprobe templates were generated using specific PCR primers containing a T7 polymerase promoter-binding site on either the forward or reverse primer to generate sense or antisense templates, respectively. The 224 base pair Tweak riboprobe template is specific for nucleotides 228-452 in the human Tweak (TNFSF12) coding domain (Genbank: AF030099). This region corresponds to coding exons 3, 4, 5 and 7 of Tweak gene.
Antisense probe specificity was confirmed using 293 cells transiently transfected with a mammalian expression vector encoding the full-length coding domain of either Fn14 or Tweak. Transfected cells were pelleted and processed for in situ analysis using either a sense or antisense probe. Only the antisense probe generated signal above background establishing the specificity of the probe sets.
MMP analysis
MMP-9 and MMP-2 levels were quantified from Eph4 culture supernatants by ELISA with Quantikine mouse pro-MMP-9 and human/mouse MMP-2 kits, respectively (R&D Systems). The MMP inhibitors used were Inhibitor-A (MMP2/MMP9 Inhibitor II; Calbiochem) and Inhibitor-B (MMP Inhibitor II; Calbiochem). Inhibitors were added to the cultures daily at the specified micromolar concentrations.
